Thyroid cancer is the most common head and neck cancer worldwide, accounting for 3% of all new cancers globally. This comprehensive review explains how doctors use imaging tests—primarily ultrasound, CT, MRI, and PET scans—to diagnose, stage, and manage the various types of thyroid carcinoma, from the most common papillary type to the rare but aggressive anaplastic form. The article covers the latest 8th edition TNM staging system, international risk-stratification guidelines for thyroid nodules, the role of genetic testing, and detailed management strategies including surgery, radioactive iodine therapy, and surveillance for recurrence. For patients, this means understanding that modern thyroid cancer care relies on a coordinated approach combining imaging, biopsy, and molecular testing to achieve the best possible outcomes.
Understanding Thyroid Cancer: A Complete Guide to Diagnosis, Staging, and Treatment Through Imaging
Table of Contents
Key Points
- Thyroid cancer is the most common head and neck cancer, with papillary type accounting for 88% of cases.
- Ultrasound is the primary imaging tool, and risk stratification systems help decide which nodules need biopsy.
- The 8th edition TNM staging system is used, and anaplastic thyroid carcinoma is always stage IV.
- Radioactive iodine therapy is used for differentiated thyroid cancer, but not for medullary or anaplastic types.
- FDG-PET/CT is valuable for detecting recurrence when thyroglobulin is elevated but radioiodine scans are negative.
Introduction: What Is Thyroid Cancer?
Thyroid cancer is the most common cancer of the head and neck region, and it ranks as the 10th most common cancer worldwide, responsible for approximately 3% of all new cancer diagnoses. The thyroid gland, located in the front of your neck, produces hormones that regulate metabolism, heart rate, and body temperature. When cells in this gland grow abnormally, they can form cancerous tumors.
There are several distinct types of thyroid cancer, each with different characteristics and prognoses. The most common type is papillary thyroid carcinoma (PTC), which accounts for about 88% of all cases. This is followed by follicular thyroid carcinoma (FTC) at 8%, medullary thyroid carcinoma (MTC) at 2–5%, poorly differentiated thyroid carcinoma (PDTC) at 6%, and the rare but highly aggressive anaplastic thyroid carcinoma (ATC) at approximately 1%.
The World Health Organization (WHO) updated its classification of thyroid tumors in 2022. Malignant (cancerous) thyroid tumors are now categorized into several groups: follicular thyroid carcinoma, invasive encapsulated follicular variant of papillary thyroid carcinoma, papillary thyroid carcinoma, oncocytic carcinoma of the thyroid, differentiated high-grade thyroid carcinoma, poorly differentiated thyroid carcinoma, and anaplastic thyroid carcinoma. There are also low-risk thyroid neoplasms, which include non-invasive follicular thyroid neoplasm with papillary-like nuclear features (a condition that behaves very benignly despite looking somewhat concerning under the microscope), follicular thyroid tumor of uncertain malignant potential, well-differentiated tumor of uncertain malignant potential, and hyalinizing trabecular thyroid tumor.
Papillary cancers that measure 1 centimeter or less are called papillary microcarcinomas (PMC), regardless of whether they have high-risk features. Most papillary and follicular thyroid cancers are considered differentiated thyroid carcinomas (DTC), meaning they retain some features of normal thyroid tissue. Medullary thyroid carcinoma arises from specialized cells called parafollicular C cells, which produce the hormone calcitonin.
Imaging plays a critical role throughout the entire journey of a thyroid cancer patient—from initial detection and characterization of suspicious nodules, to pre-surgical planning, to detecting lymph node involvement and distant metastases, and finally to identifying recurrence after treatment. This article provides a comprehensive overview of the imaging recommendations and management guidelines that doctors follow to provide optimal care for thyroid cancer patients.
Risk Factors and Symptoms
More than 90% of thyroid carcinomas occur sporadically, meaning there is no clear inherited cause. However, several risk factors have been identified that increase a person's chances of developing this disease.
Radiation exposure is a significant risk factor for papillary thyroid carcinoma. This includes a history of radiation therapy for head and neck cancers during childhood, total body radiation given before bone marrow transplantation, and exposure to ionizing radiation from nuclear fallout during childhood or adolescence. The thyroid gland is particularly sensitive to radiation, especially in young people.
Family history plays an important role in some cases. A family history of thyroid carcinoma—either alone or as part of inherited cancer syndromes—increases the risk for differentiated thyroid carcinoma and medullary thyroid carcinoma. Specifically, Type 2 multiple endocrine neoplasia (MEN) syndromes (MEN2A and MEN2B) and familial medullary thyroid carcinoma (FMTC) are known risk factors for MTC. Other inherited conditions linked to differentiated thyroid cancer include Cowden syndrome, familial adenomatous polyposis, Carney complex, and Werner syndrome.
Dietary factors also matter. Low iodine content in the diet is associated with follicular and anaplastic thyroid carcinomas. Interestingly, anaplastic thyroid carcinoma can also arise from a pre-existing papillary thyroid carcinoma in patients who have a specific genetic mutation called TERT promoter mutation.
Patients with thyroid cancer typically present with a neck swelling (a palpable lump or nodule) and hoarseness of voice. If you notice either of these symptoms, especially a new lump in your neck that persists, you should see your doctor for evaluation.
Who Gets Thyroid Cancer and Why
Thyroid carcinoma is diagnosed more frequently in women than men. Differentiated thyroid carcinoma predominantly occurs between the ages of 25 and 54 years, although any age group can be affected. This is important because thyroid cancer often strikes people during their working years and while raising families.
Elderly patients with differentiated thyroid cancer face a worse prognosis and higher recurrence rate due to more aggressive tumor characteristics and delays in diagnosis. This means that doctors need to maintain enhanced vigilance when evaluating older patients with thyroid nodules.
Sporadic medullary thyroid carcinoma typically appears between ages 40 and 60, while anaplastic thyroid carcinoma is usually diagnosed at age 65 or older. Anaplastic carcinoma is the most aggressive form and requires immediate, intensive treatment.
At the molecular level, thyroid cancers develop through specific genetic mutations. The MAPK pathway (mitogen-activated protein kinase) is essential for papillary thyroid carcinoma initiation, triggered by point mutations in the BRAF and RET genes. For follicular thyroid carcinoma, the PI3K/AKT pathway plays a crucial role, activated by mutations in RAS, PIK3CA, and AKT1 genes, along with inactivation of the PTEN tumor suppressor gene.
Medullary thyroid carcinoma originates from neuroendocrine C cells that produce calcitonin within the thyroid gland. Almost all patients (98%) with MEN2A, MEN2B, and FMTC show RET germline mutations (mutations present in every cell of the body that can be inherited). In contrast, somatic RET mutations (mutations that occur only in the tumor cells) are seen in approximately 45–70% of sporadic MTC cases.
The TERT promoter mutation is common in poorly differentiated and anaplastic thyroid carcinomas and is associated with an increased risk of distant metastases and death. Anaplastic carcinoma also frequently shows TP53 mutations, which helps distinguish it from poorly differentiated carcinoma.
Different types of thyroid cancer spread in different ways. Papillary thyroid carcinoma commonly shows regional lymph node metastases and can present with multiple (multicentric) thyroid nodules. Follicular thyroid carcinoma, on the other hand, has an increased tendency to spread to distant organs (like lungs or bones) rather than to regional lymph nodes. Classic papillary thyroid carcinoma has a good prognosis, but certain variants—including tall cell, hobnail, solid, and columnar—show more aggressive clinical behavior.
At initial presentation, approximately 48% of medullary thyroid carcinomas are localized to the thyroid gland, 35% have extathyroidal extension (spread beyond the thyroid) and regional lymph node metastasis, and 13% already have distant metastasis to the lungs, liver, or bones. Anaplastic thyroid carcinoma is highly invasive, with a high incidence of spread beyond the thyroid, lymphatic and vascular invasion, and a strong tendency for distant metastasis.
International Imaging Guidelines
Several international organizations have developed management recommendations for thyroid carcinoma. The most commonly practiced guidelines come from the American Thyroid Association (ATA), along with those from the American Association of Clinical Endocrinologists (AACE), the National Comprehensive Cancer Network (NCCN), and the European Society of Medical Oncology (ESMO).
For characterizing and risk-stratifying thyroid nodules on ultrasound, multiple international bodies have proposed systems. These include:
-
ATA guidelines (American Thyroid Association)
-
ACR TI-RADS (American College of Radiology Thyroid Imaging Reporting and Data Systems)
-
K-TIRADS (Korean Society of Thyroid Radiology)
-
EU-TIRADS (European Thyroid Association)
-
BTA guidelines (British Thyroid Association)
-
Kwak-TIRADS (developed by Kwak et al.)
-
SRU (Society of Radiologists in Ultrasound)
-
AACE/ACE/AME guidelines (American Association of Clinical Endocrinologists/American College of Endocrinology/Associazione Medici Endocrinologi)
-
F-TIRADS (French system)
-
TMC-RSS (Thyroid Multimodal-imaging Comprehensive Risk Stratification Scoring)
Each system categorizes thyroid nodules based on ultrasound features into risk categories ranging from benign (0% malignancy risk) to highly suspicious (greater than 70–90% malignancy risk). For example, the ATA system classifies nodules as benign (<1% risk), very low suspicion (<3%), low suspicion (5–10%), intermediate suspicion (10–20%), and high suspicion (>70–90%). The ACR TI-RADS system uses categories TR1 (benign) through TR5 (highly suspicious).
These risk stratification systems help doctors decide which nodules need biopsy and which can be safely monitored. The choice of system varies by region and institutional preference, but all aim to reduce unnecessary biopsies while ensuring that truly malignant nodules are not missed.
Clinical and Non-Imaging Tests
Before any imaging is performed, your doctor will conduct a thorough physical examination. This is essential to detect a palpable thyroid nodule and any enlarged cervical lymph nodes. If the thyroid nodule feels fixed (stuck) to surrounding tissues in the neck, this is concerning for thyroid carcinoma.
Blood tests are an important part of the workup. Serum thyrotropin (TSH) measurement should be performed for all patients with a thyroid nodule larger than 1 centimeter. TSH is the hormone that stimulates the thyroid gland, and its level helps determine whether the nodule is functioning normally.
Fine needle aspiration (FNA) is the gold standard for tissue diagnosis. This procedure uses a thin needle to extract cells from the nodule for microscopic examination. The decision to perform FNA is based on the ultrasound risk stratification system being used. Results are interpreted using the Bethesda System for Reporting Thyroid Cytopathology, which categorizes results from benign (Category II) through suspicious for malignancy (Category V) to malignant (Category VI).
For patients with indeterminate FNA cytology (results that are not clearly benign or malignant), additional testing may be helpful. This includes thyroid core needle biopsy and seven-gene mutation marker panels that test for BRAF, NRAS, HRAS, KRAS, RET/PTC1, RET/PTC3, and PAX8/PPARγ mutations. These genetic tests can help guide surgical decisions when cytology is unclear.
For patients suspected of having medullary thyroid carcinoma, doctors should measure serum calcitonin and carcinoembryonic antigen (CEA) levels. A markedly elevated CEA out of proportion to calcitonin indicates aggressive MTC. Elevated serum calcitonin, chromogranin, and CEA on immunohistochemistry, along with the absence of thyroglobulin staining, suggest a diagnosis of MTC.
Genetic testing is crucial for patients suspected of having MEN2 syndromes. Those suspected of MEN2A should undergo direct DNA analysis to detect RET mutations in specific exons (exon 10 codons 609, 611, 618, and 620; exon 11 codons 630 and 634; and exons 8, 13, 14, 15, and 16). Patients with the MEN2B phenotype should be tested for the RET codon M918T mutation (exon 16) and, if negative, the RET codon A883F mutation (exon 15). Genetic testing for germline RET mutations should also be offered to patients with apparent sporadic MTC, as hereditary disease may be present in 1–7% of presumed sporadic cases.
For anaplastic thyroid carcinoma, diagnosis is established by FNA biopsy with analysis of immunohistochemical markers. If the aspirate is cellular, markers on the cell block can be analyzed; otherwise, core biopsy may be required. Immunohistochemical markers that suggest ATC include BRAF V600E (which is specific and sensitive), Ki-67 greater than 30% (a marker of rapid cell division), PAX8 (retained in 40–60% of cases), and the somatic mutation of TP53. Additionally, a complete blood count, serum electrolytes, serum calcium, blood urea nitrogen, creatinine, blood glucose, liver function tests, and thyroid function tests should be part of the preliminary investigations for ATC. The expression of thyroglobulin is retained in the majority of poorly differentiated thyroid carcinomas, which helps differentiate them from anaplastic carcinoma.
Ultrasound: The Primary Imaging Tool
Ultrasound (US) is the investigation modality of choice for confirming the presence of a thyroid nodule that was incidentally detected on other imaging tests (like CT, MRI, or PET scans), for characterizing a thyroid nodule, and for ruling out metastatic cervical lymph nodes, particularly in the lateral neck compartments. It has been observed that contrast-enhanced computed tomography (CECT) has better accuracy than ultrasound for assessing central compartment lymph nodes due to technical challenges posed by the overlying thyroid gland, clavicle, and sternocleidomastoid muscle when using ultrasound for central compartment nodal evaluation.
Diagnosis is established using ultrasound-guided FNA. Aggressive variants of papillary thyroid carcinoma, such as tall cell, hobnail, solid, and columnar types, are frequently associated with extathyroidal extension, lymph node metastasis, and distant metastasis.
For optimal imaging, a high-frequency linear array probe (7–15 MHz) is used to scan the patient in a supine position (lying on the back) with the neck extended. All thyroid nodules are risk-stratified based on their ultrasound characteristics, including echogenicity (how bright the nodule appears compared to surrounding tissue), shape, margins, and the presence or absence of echogenic foci (bright spots that may represent calcifications).
Some risk stratification systems—including BTA, AACE/ACE/AME guidelines, SRU, TIRADS developed by Horvath et al., and TMC-RSS—additionally use the vascularization pattern (blood flow within the nodule) to characterize the nodule. F-TIRADS, the AACE/CE/AME guidelines, and TMC-RSS also have provisions to include sonoelastography, a technique that measures tissue stiffness. Malignant nodules tend to be harder than benign ones, and this information can help in risk assessment.
According to the 2015 ATA guidelines, ultrasound findings with a high suspicion of malignancy (>70–90%) include a solid hypoechoic nodule (a nodule that appears darker than the surrounding thyroid tissue), a solid hypoechoic component of a partially cystic nodule, and one or more of the following features: irregular margins (infiltrative or microlobulated), microcalcifications (tiny calcium deposits), taller-than-wide shape, rim calcifications with a small extrusive soft tissue component, and evidence of extathyroidal extension.
Several studies have compared the diagnostic performance of these various ultrasound-based risk stratification systems. One study by Grani et al. found that unnecessary FNAs were avoided in 30.7% of cases using BTA, 17.1% with EU-TIRADS, 53.4% with K-TIRADS, 34.9% with ACR-TIRADS, and 43.8% with Kwak-TIRADS. The best performance was achieved by ACR-TIRADS with a false negative rate of only 2.2%, sensitivity of 86.1%, specificity of 32%, positive predictive value of 8.9%, and negative predictive value of 96.7%.
Another study by Peng et al. showed good performance by ACR-TIRADS, ATA, and AACE/ACE/AME systems, with sensitivities ranging from 88.3% to 94.9% and specificities from 58.1% to 75.3%. Chng et al. found that BTA, Kwak-TIRADS, and ATA have high sensitivity and negative predictive value. Shen et al. demonstrated good diagnostic performances by EU-TIRADS, ACR-TIRADS, Kwak-TIRADS, and ATA, with area under the curve values exceeding 86%. Xu et al. found the lowest rate of unnecessary FNA with ACR-TIRADS and the most effective diagnostic performance in specificity with K-TIRADS. Marukatat et al. reported similar results with K-TIRADS and EU-TIRADS for predicting malignancy.
In addition to evaluating the thyroid gland itself, the ultrasound examination should also assess for underlying diffuse inflammatory conditions, such as Hashimoto's thyroiditis, which can affect the appearance of the thyroid and the risk of malignancy.
Evaluating Neck Lymph Nodes
Ultrasound evaluation of the neck—from the submental region (under the chin) to the sternal notch (the dip at the base of the neck)—is an essential component of the thyroid ultrasound examination. This is because thyroid cancer frequently spreads to lymph nodes in the neck, and detecting this spread is crucial for treatment planning.
In addition to thyroid nodule characteristics, cervical lymph node status is incorporated into several risk stratification systems, including AACE/CE/AME guidelines, F-TIRADS, BTA, ATA, K-TIRADS, and TMC-RSS. Nodal metastasis from thyroid cancer is most common in the central compartment (level VI) and the lateral group of nodes (levels II to IV).
The incidence of nodal metastasis varies by cancer type. Papillary thyroid carcinoma shows a high incidence of nodal metastasis, ranging from 30 to 90%. The incidence rates for medullary thyroid carcinoma, anaplastic thyroid carcinoma, and follicular thyroid carcinoma are approximately 50%, 40%, and 10%, respectively.
Ultrasound features that predict nodal metastasis include:
-
Microcalcifications (tiny calcium deposits within the node)
-
Cystic components (fluid-filled areas within the node)
-
Peripheral vascularity (blood flow at the edge of the node rather than in the center)
-
Hyperechogenicity (the node appears brighter than surrounding muscle)
-
Round shape (normal lymph nodes are oval or kidney-shaped)
-
Loss of fatty hilum (the central fatty area of a normal lymph node disappears)
-
Extranodal extension (ENE) (cancer spreading beyond the lymph node capsule)
Hyperechogenicity, microcalcifications, and cystic components are common in nodal metastasis from papillary thyroid carcinoma, whereas necrosis (tissue death) and extranodal extension are more common in metastasis from anaplastic thyroid carcinoma.
Ultrasound-Guided Fine Needle Aspiration (Biopsy)
FNA of the thyroid nodule should be conducted based on the ultrasound risk stratification criteria, and FNA should also be performed from any suspicious cervical lymph nodes. As shown in the comparison studies, unnecessary FNAs are reduced significantly by using ACR-TIRADS. When three or more thyroid nodules qualify for biopsy according to the ACR TI-RADS guidelines, the two most suspicious nodules should be biopsied.
If the serum TSH in a patient with a thyroid nodule larger than 1 cm is subnormal (suggesting an overactive nodule), the patient should additionally undergo a radionuclide thyroid scan (preferably using iodine-123), and the findings should be compared with ultrasound features. Only hypofunctioning (cold) nodules that meet the ultrasound criteria for FNA should be biopsied, because hyperfunctioning (hot) nodules are rarely malignant.
Before performing FNA biopsy, informed consent should be obtained from the patient. The procedure involves the following steps:
- Localize the nodule on ultrasound
- Clean the overlying skin with a 10% povidone-iodine solution
- Optionally inject approximately 1–2 mL of 1% lidocaine hydrochloride solution into the skin and superficial subcutaneous tissue overlying the nodule for local anesthesia
- Perform the FNA using a 23–27-gauge needle
A parallel technique is used for superficial nodules, where the needle is visualized in its entirety. For nodules situated deep within the thyroid gland, a perpendicular technique is used, and only the tip of the needle is visualized. The tip of the needle should be placed at the center of the nodule or neck node being biopsied.
Three to four needle passes with either the capillary technique (to-and-fro movement of the needle within the nodule without suction) or the aspiration technique (with suction) is sufficient if an on-site cytopathologist for evaluation of adequacy is not available. For a core needle biopsy in the case of a non-diagnostic FNA, an 18–20-gauge needle should be used.
Thyroglobulin (Tg) estimation in the washout fluid from lymph node FNA biopsy can provide preoperative information about nodal metastasis and has added value in FNA biopsy. This is particularly useful when cytology is inconclusive but metastatic thyroid cancer is suspected.
Staging: How Cancer Is Classified
Currently, the 8th edition of the tumor, node, metastasis (TNM) staging system proposed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) is being utilized for thyroid cancer. This system classifies cancer based on three key pieces of information:
-
T – the size and extent of the primary tumor
-
N – whether cancer has spread to nearby lymph nodes
-
M – whether cancer has spread (metastasized) to distant organs
Though the TNM descriptors for differentiated carcinoma and anaplastic carcinoma are the same, the prognostic stage groups are different because all anaplastic thyroid carcinomas are categorized as stage IV (A-C). This reflects the extremely aggressive nature of this cancer type.
For extensive and invasive disease or clinically obvious neck nodes, contrast-enhanced computed tomography (CECT) or contrast-enhanced magnetic resonance imaging (MRI) of the neck is recommended as an additional investigation according to the 2015 ATA guidelines for differentiated thyroid carcinoma. These cross-sectional imaging studies provide detailed anatomical information that helps surgeons plan the extent of surgery needed.
Advanced Imaging: CT, MRI, and PET Scans
While ultrasound is the primary imaging modality for thyroid cancer, computed tomography (CT), magnetic resonance imaging (MRI), and fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT) play important roles in specific situations.
CT scans use X-rays to create detailed cross-sectional images of the body. In thyroid cancer, contrast-enhanced CT of the neck is recommended for staging when there is extensive or invasive disease, or when there are clinically obvious neck nodes. CT is particularly useful for evaluating the central compartment lymph nodes, which can be difficult to assess with ultrasound due to the overlying thyroid gland, clavicle, and sternocleidomastoid muscle. CT also provides excellent evaluation of the chest for detecting lung metastases.
MRI uses magnetic fields and radio waves to create detailed images. It provides excellent soft tissue contrast, making it valuable for evaluating the extent of tumor invasion into surrounding structures, such as the trachea (windpipe), esophagus (food pipe), and major blood vessels. MRI is particularly useful for assessing extathyroidal extension and involvement of the aerodigestive tract.
FDG-PET/CT combines a CT scan with a positron emission tomography scan that detects areas of high metabolic activity. Cancer cells are typically more metabolically active than normal cells, so they show up as bright areas on the PET scan. FDG-PET/CT is particularly valuable in the following situations:
- Evaluating patients with elevated thyroglobulin levels but negative radioiodine scans (suspected recurrence that doesn't take up iodine)
- Staging aggressive thyroid cancer variants
- Detecting distant metastases
- Assessing response to treatment in advanced disease
The specific imaging recommendations for staging medullary and anaplastic thyroid carcinomas are based on ATA guidelines. For medullary thyroid carcinoma, imaging typically includes ultrasound of the neck, CT of the chest and mediastinum, and CT or MRI of the liver. For anaplastic thyroid carcinoma, urgent cross-sectional imaging with CT or MRI of the neck and chest is recommended to assess the extent of disease and airway involvement.
Treatment and Management Strategies
The management of thyroid carcinoma depends on the type of cancer, its stage, and individual patient factors. The American Thyroid Association guidelines provide the framework for treatment decisions.
Surgery is the primary treatment for most thyroid cancers. The extent of surgery depends on the type and stage of cancer:
-
Lobectomy (removal of one lobe of the thyroid) may be sufficient for small, low-risk papillary microcarcinomas
-
Total thyroidectomy (removal of the entire thyroid gland) is recommended for most thyroid cancers, especially those larger than 1 cm, those with lymph node involvement, or those with aggressive features
-
Central neck dissection (removal of lymph nodes in the central compartment) is performed when there is evidence of lymph node metastasis
-
Lateral neck dissection (removal of lymph nodes in the lateral compartments) is performed when there is evidence of metastasis to these nodes
For medullary thyroid carcinoma, total thyroidectomy with central neck dissection is the standard surgical approach. Because MTC arises from C cells that do not take up iodine, radioactive iodine therapy is not effective for this type of cancer. Instead, treatment focuses on complete surgical removal and management of metastatic disease.
For anaplastic thyroid carcinoma, treatment is urgent and aggressive. Because this cancer grows rapidly and is highly invasive, treatment typically involves a combination of surgery (when feasible), radiation therapy, and chemotherapy. The goal is to control the disease and maintain airway patency. Even with aggressive treatment, the prognosis for anaplastic thyroid carcinoma remains poor, and palliative care is an important component of management.
For differentiated thyroid carcinoma (papillary and follicular), treatment typically involves surgery followed by radioactive iodine (RAI) therapy in selected patients. The decision to use RAI depends on the risk of recurrence, which is determined by the tumor characteristics, lymph node status, and other factors.
Radioactive Iodine Therapy
Radioactive iodine (RAI) therapy is a targeted treatment used for differentiated thyroid carcinoma. Because thyroid cells (both normal and cancerous) take up iodine, radioactive iodine can be used to destroy remaining thyroid tissue and cancer cells after surgery.
The role of a radioiodine scan is crucial in this context. After thyroidectomy, patients may undergo a diagnostic radioiodine scan to determine whether any thyroid tissue or cancer remains. This scan uses a small amount of radioactive iodine to identify areas of iodine uptake in the body.
RAI therapy is typically recommended for patients with:
- Tumors larger than 4 cm
- Tumors with extathyroidal extension
- Lymph node metastases
- Distant metastases
- Aggressive histologic subtypes
For patients with low-risk disease (small tumors, no lymph node involvement, complete surgical resection), the trend in recent years has been toward more conservative management, with some patients not requiring RAI therapy at all. This reflects a growing understanding that not all thyroid cancers behave aggressively and that overtreatment can cause unnecessary side effects.
Before RAI therapy, patients typically need to follow a low-iodine diet for 1–2 weeks to maximize iodine uptake by any remaining thyroid tissue or cancer cells. They may also receive recombinant human TSH (thyrotropin alfa) injections or undergo thyroid hormone withdrawal to stimulate TSH levels, which increases iodine uptake.
After RAI therapy, patients undergo a post-treatment scan to assess the extent of iodine uptake and to detect any remaining disease. This scan helps guide further management decisions.
Managing Recurrent Disease
Despite optimal initial treatment, thyroid cancer can recur. The management of recurrent disease depends on the location and extent of recurrence.
Ultrasound is the primary imaging modality for detecting recurrent disease in the thyroid bed (the area where the thyroid was removed) and in cervical lymph nodes. Suspicious findings on ultrasound can be confirmed with ultrasound-guided FNA.
For patients with elevated thyroglobulin levels but negative radioiodine scans, FDG-PET/CT is particularly valuable. This situation, known as "thyroglobulin-positive, iodine-negative" disease, suggests the presence of cancer cells that have lost their ability to take up iodine—a sign of more aggressive disease. FDG-PET/CT can localize these metabolically active cancer cells, guiding further treatment.
Treatment options for recurrent disease include:
-
Surgery – for resectable recurrence in the neck
-
Radioactive iodine therapy – for iodine-avid recurrence
-
External beam radiation therapy – for disease that cannot be surgically removed or that doesn't respond to RAI
-
Systemic therapy – for metastatic disease, including tyrosine kinase inhibitors (such as lenvatinib and sorafenib) for progressive disease that doesn't respond to other treatments
-
Observation – for small, stable recurrences that are not growing or causing symptoms
For medullary thyroid carcinoma, recurrent or metastatic disease is managed with surgery for resectable disease, and systemic therapy with tyrosine kinase inhibitors (such as vandetanib and cabozantinib) for progressive metastatic disease. Serum calcitonin and CEA levels are used to monitor disease status.
For anaplastic thyroid carcinoma, recurrence is managed with a focus on palliative care, maintaining airway patency, and controlling symptoms. Clinical trials may be available for patients with this aggressive cancer.
Study Limitations
This comprehensive review has several limitations that should be acknowledged. First, it is a review article rather than an original research study, meaning it synthesizes existing evidence rather than presenting new data. The recommendations are based on the available literature and expert consensus, which may evolve as new evidence emerges.
Second, the various ultrasound risk stratification systems have been compared in different studies with different patient populations, and the results may not be directly comparable. The performance of these systems can vary depending on the prevalence of thyroid cancer in the studied population, the experience of the sonographers, and the specific criteria applied.
Third, the field of thyroid cancer management is rapidly evolving, with new molecular markers, targeted therapies, and imaging techniques being developed. Some recommendations may become outdated as new evidence becomes available.
Fourth, the review focuses primarily on imaging recommendations and management guidelines from Western organizations (ATA, AACE, NCCN, ESMO). Guidelines from other regions, such as Asia and Latin America, may differ in some respects, and these differences are not fully addressed in this article.
Finally, the review does not provide patient-level outcomes data, so it cannot directly assess the impact of following these imaging recommendations on patient survival or quality of life. Future research should focus on validating these recommendations in diverse patient populations and assessing their impact on clinically meaningful outcomes.
Recommendations for Patients
If you or a loved one has been diagnosed with thyroid cancer or a suspicious thyroid nodule, here are some key recommendations based on this comprehensive review:
-
Seek care at a specialized center – Thyroid cancer management requires a multidisciplinary team including endocrinologists, surgeons, radiologists, pathologists, and nuclear medicine physicians. Specialized centers with experience in thyroid cancer typically achieve better outcomes.
-
Ensure complete imaging evaluation – A thorough ultrasound examination of both the thyroid and the neck lymph nodes is essential. If you have advanced disease or clinically obvious neck nodes, additional imaging with CT or MRI may be needed.
-
Understand your risk stratification – Ask your doctor about your thyroid nodule's risk category based on ultrasound features. This determines whether biopsy is needed and how urgently.
-
Complete all recommended genetic testing – If you have medullary thyroid carcinoma or a family history of thyroid cancer, genetic testing for RET mutations is essential. This can identify hereditary syndromes that affect not only you but also your family members.
-
Discuss the extent of surgery – The extent of surgery (lobectomy vs. total thyroidectomy) depends on your specific cancer type, size, and risk factors. Discuss the risks and benefits of each approach with your surgical team.
-
Ask about radioactive iodine therapy – Not all patients with differentiated thyroid cancer need RAI therapy. Ask your doctor whether your risk profile warrants this treatment and what the potential side effects are.
-
Follow up regularly – After treatment, regular follow-up with ultrasound, blood tests (thyroglobulin, calcitonin), and other imaging as needed is essential for detecting recurrence early.
-
Consider clinical trials – For advanced or recurrent disease that doesn't respond to standard treatments, clinical trials of new targeted therapies may be an option. Discuss this with your oncologist.
-
Maintain a healthy lifestyle – While there is no specific diet that prevents thyroid cancer recurrence, maintaining a healthy lifestyle with adequate iodine intake (not excessive, not deficient) and regular exercise supports overall health and well-being.
-
Seek psychological support – A cancer diagnosis is stressful. Support groups, counseling, and connecting with other thyroid cancer survivors can help you cope with the emotional aspects of your journey.
Remember that thyroid cancer, particularly the differentiated types, has an excellent prognosis when detected and treated appropriately. The 10-year survival rate for papillary thyroid carcinoma exceeds 95%. Even with recurrence, many patients live for many years with good quality of life. Stay informed, ask questions, and be an active participant in your healthcare decisions.
Frequently Asked Questions
How is a thyroid nodule evaluated for cancer?
Ultrasound is the primary imaging test to characterize thyroid nodules. Based on ultrasound features like echogenicity, margins, and calcifications, nodules are placed into risk categories. If a nodule is suspicious, an ultrasound-guided fine needle aspiration (FNA) biopsy is performed to obtain cells for diagnosis.
What does the TNM staging system mean for thyroid cancer?
The TNM system classifies cancer based on the tumor size and extent (T), lymph node involvement (N), and distant metastasis (M). For thyroid cancer, the 8th edition is used. Anaplastic thyroid carcinoma is always stage IV, reflecting its aggressive nature, while differentiated cancers have varying stages.
When is radioactive iodine therapy used for thyroid cancer?
Radioactive iodine (RAI) therapy is used for differentiated thyroid cancer (papillary and follicular) after surgery. It is typically recommended for tumors larger than 4 cm, tumors with extathyroidal extension, lymph node metastases, distant metastases, or aggressive histologic subtypes. Low-risk patients may not need RAI.
What is the role of CT, MRI, and PET scans in thyroid cancer?
CT and MRI are used for staging when there is extensive disease or clinically obvious neck nodes, providing detailed anatomy. FDG-PET/CT is valuable for detecting recurrence in patients with elevated thyroglobulin but negative radioiodine scans, and for staging aggressive variants and detecting distant metastases.
How is medullary thyroid carcinoma different from other types?
Medullary thyroid carcinoma arises from parafollicular C cells and does not take up iodine, so radioactive iodine therapy is not effective. Treatment focuses on total thyroidectomy with central neck dissection. Genetic testing for RET mutations is essential, as hereditary syndromes may be present.
What should I do if I have a thyroid nodule?
See your doctor for a physical exam and ultrasound. Based on ultrasound risk stratification, your doctor will decide if a biopsy is needed. If you have symptoms like a neck lump or hoarseness, seek evaluation promptly. Follow your doctor's recommendations for monitoring or treatment.
Source Information
Original Article Title: Comprehensive Review of the Imaging Recommendations for Diagnosis, Staging, and Management of Thyroid Carcinoma
DOI: 10.3390/jcm13102904
Authors: Nivedita Chakrabarty, Abhishek Mahajan, Sandip Basu, and Anil K. D'Cruz
Journal: Journal of Clinical Medicine, 2024, Volume 13, Issue 10, Article 2904
Publication Date: May 14, 2024
DOI: 10.3390/jcm13102904
Affiliations: Department of Radiodiagnosis, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Mumbai, India; Department of Imaging, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK; Faculty of Health and Life Sciences, University of Liverpool, UK; Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, India; Apollo Hospitals, Navi Mumbai, India; Foundation of Head Neck Oncology, Mumbai, India; Union International Cancer Control (UICC), Geneva, Switzerland.
Note: This patient-friendly article is based on peer-reviewed research published in the Journal of Clinical Medicine. It has been adapted to make the information accessible to patients and their families while preserving all key data, findings, and recommendations from the original publication. This article is for educational purposes and should not replace professional medical advice. Always consult your healthcare provider regarding your specific medical condition and treatment options.
